Weight loss drug combo trial pulled before it even started

NCT ID NCT05209984

Terminated Disease control Sponsor: Eurofarma Laboratorios S.A. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a planned phase 3 study to test a new combination of two drugs, sibutramine and topiramate, for weight loss in overweight and obese adults. The study aimed to see if the combination worked better than either drug alone or a placebo. However, the trial was withdrawn before enrolling any participants, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sibutramine and topiramate combination
What this could lead to: If successful, this could provide a new weight-loss medication option for adults who are overweight or obese.
What could go wrong: The trial was withdrawn before any participants were enrolled, so no results are available. Sibutramine has known safety concerns, including cardiovascular risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Eurofarma Laboratórios S.A

São Paulo, São Paulo, 06696-000, Brazil
HC-FMUSP

São Paulo, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.